Alliance Global raised its price target on Sellas Life Sciences to $10, implying a 92% upside potential while maintaining a 'Buy' rating on StockTwits. The decision follows positive updates on the company's AML treatments, SLS009 and Galinpepimut-S. Sellas is also set to present preclinical data at the American Association for Cancer Research conference.